As trial against OpenAI begins, Elon Musk seeks Sam Altman’s ouster

The trial against OpenAI has begun, with Elon Musk seeking to overturn OpenAI's shift toward a for-profit structure and to force the return of tens of billions of dollars in alleged ill-gotten gains. Musk is also asking for Sam Altman's removal from OpenAI's nonprofit board and for Altman and Greg Brockman to be removed as officers of the for-profit entity. OpenAI argues Musk backed the for-profit conversion and says the case is really about control of the company rather than its mission.

Analysis

The market is likely underpricing the governance overhang more than the legal merits. Even if Musk loses, the trial forces a public record on how much control and economic benefit flowed through the conversion path, which raises the probability of a slower, more negotiated restructuring of OpenAI’s cap table and control rights rather than an immediate business disruption. That matters most for MSFT because the stock is not just exposed to OpenAI economics; it is exposed to the optionality embedded in having a privileged partner that could become a litigation-constrained counterparty.

Second-order, this is a control premium compression story. The headline risk is not a binary injunction; it is the possibility that investors and regulators start demanding clearer separations between nonprofit governance, model access, and commercial monetization. That would likely pressure OpenAI’s ability to move quickly on enterprise distribution, licensing terms, and strategic partnerships, which indirectly benefits fast followers that can sell “good enough” AI without governance baggage.

For TSLA, the direct equity read-through is muted, but the trial reactivates a longstanding issue: Musk’s attention and credibility are finite resources. Any prolonged deposition/testimony cycle increases the odds of distraction exactly when Tesla needs execution discipline, and that can matter more than any abstract AI narrative. The contrarian view is that the lawsuit may actually validate OpenAI’s moat by proving how hard it is to build frontier AI without large-scale capital and centralized decision-making, which could reduce the probability of a meaningful unwind.

Near term, the key catalyst window is 2-6 weeks as executives testify and discovery surfaces internal intent. The tail risk is not a winner-take-all judgment; it is a settlement that clarifies governance while leaving the economics intact, which would remove uncertainty for MSFT but likely preserve a valuation haircut versus a clean story. If the court appears sympathetic to Musk’s control arguments, expect volatility in AI proxy names and a rotation toward diversified software beneficiaries with less single-partner exposure.

Key Decisions for Investors

• Underweight MSFT on a 1-2 month horizon versus software peers; the risk/reward is skewed by governance uncertainty and asymmetric headline risk even if the core AI franchise remains intact.
• Pair trade: long diversified enterprise software basket, short MSFT into trial testimony dates; thesis is that ‘AI without single-counterparty dependence’ should outperform if OpenAI control risk expands.
• Avoid adding TSLA ahead of Musk testimony; any incremental upside from AI optionality is outweighed by distraction risk and the probability of renewed governance overhang.
• Buy downside protection in MSFT via 6-8 week puts or put spreads to monetize potential multiple compression if the court record suggests conversion impropriety or forced restructuring.
• If the market sells off OpenAI-adjacent names on headline risk, use that to add selectively to beneficiaries with model-agnostic AI monetization, as the likely end state is restructuring noise, not an AI spending collapse.